Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

Table 3 Multivariable analysis examining the relationship between change in CXCL4 from baseline to 12 months and the course of FVC from 12 to 24 months (N = 97)

Baseline covariate	Estimate	95% CI	P value
ΔCXCL4	−1.232	−2.405, −0.060	0.040
Baseline FVC	0.972	0.807, 1.138	<0.0001
Baseline QILD/QLF^a	0.297	−0.496, 1.089	0.464
Treatment arm	−0.361	−3.182, 2.460	0.802

^aDefined as the first principal component from a principal component analysis of the following variables: QILD-LM, QILD-WL, QLF-LM, and QLF-WL
FVC forced vital capacity, CI confidence interval, QLF quantitative extent of lung fibrosis on high-resolution chest computed tomography, QILD quantitative extent of total interstitial lung disease (including fibrosis, honeycomb, and ground glass opacity), WL whole lung, LM lobe of maximal involvement

ISSN: 1478-6362